Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Holders of 5% or more of AVTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Avalo Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Biotechnology Value Fund L P | 13G/A | 9.99%2.35M shares | 0.00 ppfrom 9.99% | Feb 14, 20254 filings | May 15, 2026 | SEC |
| Commodore Capital LP | 13G | 9.90%5.72M shares | New | Jun 18, 20261 filing | Jun 18, 2026 | SEC |
| Ra Capital Management, L.P. | 13G/A | 9.90%2.46M shares | 0.00 ppfrom 9.90% | May 15, 20254 filings | May 15, 2026 | SEC |
| T. Rowe Price Investment Management, Inc. | 13G | 9.50%2.16M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| Nantahala Capital Management, LLC | 13G/A | 9.39%1.24M shares | +0.96 ppfrom 8.43% | May 15, 20252 filings | Nov 14, 2025 | SEC |
| Caligan Partners LP | 13G/A | 7.20%1.64M shares | +2.30 ppfrom 4.90% | Nov 14, 20253 filings | May 15, 2026 | SEC |
| FMR LLC | 13G/A | 6.10%3.19M shares | −5.40 ppfrom 11.50% | Mar 6, 20262 filings | Jun 5, 2026 | SEC |
| Deep Track Capital, LP | 13G | 5.81%3.06M shares | +5.81 ppfrom 0.00% | Nov 14, 20252 filings | May 29, 2026 | SEC |
| Avoro Capital Advisors LLC | 13G | 5.75%1.41M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| Affinity Asset Advisors, LLC | 13G/A | 5.70%1.05M shares | −1.95 ppfrom 7.65% | Dec 31, 20243 filings | Jan 29, 2026 | SEC |
| Point72 Asset Management, L.P. | 13G | 5.20%2.71M shares | +1.70 ppfrom 3.50% | Aug 5, 20254 filings | May 26, 2026 | SEC |
| Millennium Management LLC | 13G | 5.00%934.4K shares | +0.20 ppfrom 4.80% | Feb 3, 20264 filings | Feb 24, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
44 Schedule 13D and 13G filings on Avalo Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jun 18, 20264:29 PM ET | Commodore Capital LPand 3 others | 13G | 9.90%5.72M shares | New | Jun 11, 2026 | SEC |
| Jun 5, 202610:13 AM ET | FMR LLCand 1 other | 13G/A | 6.10%3.19M shares | −5.40 ppfrom 11.50% | May 29, 2026 | SEC |
| May 29, 20264:37 PM ET | Deep Track Capital, LPand 2 others | 13G | 5.81%3.06M shares | +5.81 ppfrom 0.00% | May 22, 2026 | SEC |
| May 26, 20265:10 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 5.20%2.71M shares | +1.70 ppfrom 3.50% | May 22, 2026 | SEC |
| May 15, 20266:41 PM ET | Logos Global Management LPand 4 others | 13G/A | 3.20%1.68M shares | –Below 5% | Mar 31, 2026 | SEC |
| May 15, 20264:34 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%2.46M shares | 0.00 ppfrom 9.90% | Mar 31, 2026 | SEC |
| May 15, 20264:31 PM ET | OrbiMed Advisors LLC | 13G/A | 2.10%475.2K shares | −4.30 ppfrom 6.40%Below 5% | Mar 31, 2026 | SEC |
| May 15, 20264:04 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%2.35M shares | 0.00 ppfrom 9.99% | Mar 31, 2026 | SEC |
| May 15, 202610:31 AM ET | Caligan Partners LPand 1 other | 13G/A | 7.20%1.64M shares | +2.30 ppfrom 4.90% | Mar 31, 2026 | SEC |
| May 15, 202610:06 AM ET | T. Rowe Price Investment Management, Inc. | 13G | 9.50%2.16M shares | New | Mar 31, 2026 | SEC |
| May 15, 20268:15 AM ET | Avoro Capital Advisors LLCand 1 other | 13G | 5.75%1.41M shares | New | Mar 31, 2026 | SEC |
| Mar 6, 202610:05 AM ET | FMR LLCand 1 other | 13G | 11.50%2.13M shares | New | Feb 27, 2026 | SEC |
| Feb 24, 20264:48 PM ET | Millennium Management LLCand 2 others | 13G | 5.00%934.4K shares | +0.20 ppfrom 4.80% | Feb 17, 2026 | SEC |
| Feb 17, 20266:13 PM ET | OrbiMed Advisors LLC | 13G/A | 6.40%1.19M shares | −2.50 ppfrom 8.90% | Dec 31, 2025 | SEC |
| Feb 17, 20265:00 PM ET | Caligan Partners LPand 1 other | 13G/A | 4.90%881.5K shares | −1.40 ppfrom 6.30%Below 5% | Dec 31, 2025 | SEC |
| Feb 17, 20264:33 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 3.50%627.5K shares | −4.50 ppfrom 8.00%Below 5% | Dec 31, 2025 | SEC |
| Feb 17, 20264:21 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%1.94M shares | 0.00 ppfrom 9.90% | Dec 31, 2025 | SEC |
| Feb 17, 20264:11 PM ET | Millennium Management LLCand 2 others | 13G | 4.80%887.3K shares | −0.10 ppfrom 4.90%Below 5% | Feb 10, 2026 | SEC |
| Feb 17, 20264:07 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%1.90M shares | 0.00 ppfrom 9.99% | Dec 31, 2025 | SEC |
| Feb 17, 20266:57 AM ET | Balyasny Asset Management LLCand 4 others | 13G/A | 2.42%439.3K shares | −3.80 ppfrom 6.22%Below 5% | Dec 31, 2025 | SEC |
| Feb 10, 20264:07 PM ET | Millennium Management LLCand 2 others | 13G | 4.90%906.8K shares | 0.00 ppfrom 4.90%Below 5% | Feb 3, 2026 | SEC |
| Feb 10, 202611:36 AM ET | Silverarc Capital Management, LLCand 1 other | 13G | 2.83%524.4K shares | −2.65 ppfrom 5.48%Below 5% | Dec 31, 2025 | SEC |
| Feb 3, 20265:19 PM ET | Millennium Management LLCand 2 others | 13G | 4.90%905.8K shares | NewBelow 5% | Jan 28, 2026 | SEC |
| Jan 30, 20261:25 PM ET | Vanguard Group Inc | 13G/A | 4.43%804.1K shares | −0.83 ppfrom 5.26%Below 5% | Dec 31, 2025 | SEC |
| Jan 29, 20267:56 PM ET | Affinity Asset Advisors, LLCand 1 other | 13G/A | 5.70%1.05M shares | −1.95 ppfrom 7.65% | Jan 22, 2026 | SEC |
| Nov 14, 20256:26 PM ET | Ikarian Capital, LLCand 1 other | 13G/A | 3.80%712.0K shares | −6.19 ppfrom 9.99%Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 20254:54 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 9.39%1.24M shares | +0.96 ppfrom 8.43% | Sep 30, 2025 | SEC |
| Nov 14, 20254:12 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%1.39M shares | 0.00 ppfrom 9.90% | Sep 30, 2025 | SEC |
| Nov 14, 20254:11 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 8.00%1.05M shares | +2.60 ppfrom 5.40% | Sep 30, 2025 | SEC |
| Nov 14, 20254:00 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%1.46M shares | 0.00 ppfrom 9.99% | Sep 30, 2025 | SEC |
| Nov 14, 20252:31 PM ET | Caligan Partners LPand 1 other | 13G | 6.30%833.3K shares | New | Sep 30, 2025 | SEC |
| Nov 14, 202512:39 PM ET | Silverarc Capital Management, LLCand 1 other | 13G | 5.48%720.9K shares | New | Sep 30, 2025 | SEC |
| Nov 14, 20258:09 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 0.00%0 shares | –Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 20256:01 AM ET | Balyasny Asset Management LLCand 4 others | 13G | 6.22%817.4K shares | New | Sep 30, 2025 | SEC |
| Nov 13, 20255:21 PM ET | Affinity Asset Advisors, LLCand 1 other | 13G/A | 7.65%1.01M shares | +2.35 ppfrom 5.30% | Sep 30, 2025 | SEC |
| Oct 30, 20252:04 PM ET | Vanguard Group Inc | 13G | 5.26%692.6K shares | New | Sep 30, 2025 | SEC |
| Aug 27, 20255:00 PM ET | Crutcher Patrick J | 13G/A | 4.20%549.5K shares | –Below 5% | Aug 6, 2025 | SEC |
| Aug 14, 20256:00 PM ET | OrbiMed Advisors LLCand 1 other | 13G/A | 8.90%967.0K shares | – | Jun 30, 2025 | SEC |
| Aug 5, 20254:58 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 5.40%588.6K shares | New | Aug 4, 2025 | SEC |
| May 15, 20255:33 PM ET | Ikarian Capital, LLCand 1 other | 13G/A | 9.99%1.19M shares | – | Mar 31, 2025 | SEC |
| May 15, 20254:49 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%1.09M shares | – | Mar 31, 2025 | SEC |
| May 15, 20254:36 PM ET | Nantahala Capital Management, LLCand 2 others | 13G | 8.43%900.0K shares | New | Mar 31, 2025 | SEC |
| Feb 14, 20254:02 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%1.04M shares | – | Dec 31, 2024 | SEC |
| Dec 31, 20244:13 PM ET | Affinity Asset Advisors, LLCand 1 other | 13G | 5.30%550.8K shares | New | Dec 23, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Avalo Therapeutics, Inc. shares.
No Form 144 notices for Avalo Therapeutics, Inc. are on file.